BeiGene announces data from two clinical trials of Brukinsa at ASH meeting
BeiGene announced clinical data from three trials of its BTK inhibitor Brukinsa were presented at the 61st American Society of Hematology Annual Meeting. In two oral presentations of Brukinsa in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, the drug candidate demonstrated consistent safety and a high overall response rate; in the poster presentation of Brukinsa combined with BeiGene's investigational anti-PD-1 antibody tislelizumab in patients with previously treated B-cell malignancies, the combination treatment showed preliminary efficacy and was generally well tolerated. "The results presented today on Brukinsa, a BTK inhibitor designed to maximize target occupancy and minimize off-target binding, demonstrated robust clinical activity and a safety profile consistent with what we've observed to date in our clinical trials, including safety data that supported the recent U.S. FDA accelerated approval in patients with previously treated mantle cell lymphoma," said Jane Huang, M.D., Chief Medical Officer, hematology at BeiGene. "CLL or SLL is the most common type of leukemia in adults, and despite the advancements of BTK inhibitor therapy for these cancers, there remains a need for highly selective BTK inhibitors capable of promoting long-term responses, and with a safety profile that is tolerable over time. The results presented here today further demonstrate the potential for Brukinsa to help people living with these persistent, life-threatening cancers."